AR079197A1 - Polipeptidos inmunomoduladores derivados de la il-2 y su uso terapeutico en cancer y en infecciones cronicas - Google Patents
Polipeptidos inmunomoduladores derivados de la il-2 y su uso terapeutico en cancer y en infecciones cronicasInfo
- Publication number
- AR079197A1 AR079197A1 ARP100104366A ARP100104366A AR079197A1 AR 079197 A1 AR079197 A1 AR 079197A1 AR P100104366 A ARP100104366 A AR P100104366A AR P100104366 A ARP100104366 A AR P100104366A AR 079197 A1 AR079197 A1 AR 079197A1
- Authority
- AR
- Argentina
- Prior art keywords
- polypeptides
- cancer
- sequence
- therapeutic use
- disclosed
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Polipéptidos cuya secuencia primaria tiene una alta homología con la secuencia de la InterleuCina 2 humana (IL-2) con algunas mutaciones puntuales en la secuencia de la lL-2 nativa. Dichos polipéptidos tienen un efecto inmunomodulador sobre el sistema inmune, que es selectivo/preferencial sobre células T reguladoras. también se relaciona con polipéptidos específicos cuya secuencia de aminoácidos es divulgada en la presente. En otro aspecto se relaciona con las composiciones farmacéuticas que comprenden como principio activo los polipéptidos divulgados. Por ultimo, se relaciona con el uso terapéutico de los polipéptidos y composiciones farmacéuticas divulgados dado su efecto modulador del sistema inmune sobre patologías como cáncer y enfermedades infecciosas cronicas. Proteína de fusion que comprende el polipéptido inmunomodulador y una proteína transportadora.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20090203A CU23734A1 (es) | 2009-11-27 | 2009-11-27 | Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR079197A1 true AR079197A1 (es) | 2012-01-04 |
Family
ID=43646474
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100104366A AR079197A1 (es) | 2009-11-27 | 2010-11-25 | Polipeptidos inmunomoduladores derivados de la il-2 y su uso terapeutico en cancer y en infecciones cronicas |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US8759486B2 (es) |
| EP (1) | EP2505206B1 (es) |
| JP (1) | JP5680661B2 (es) |
| KR (1) | KR101484590B1 (es) |
| CN (1) | CN102665754B (es) |
| AR (1) | AR079197A1 (es) |
| AU (1) | AU2010324254B2 (es) |
| BR (1) | BR112012012025B8 (es) |
| CA (1) | CA2781173C (es) |
| CL (1) | CL2012001030A1 (es) |
| CO (1) | CO6501124A2 (es) |
| CU (1) | CU23734A1 (es) |
| EA (1) | EA021867B1 (es) |
| EC (1) | ECSP12011803A (es) |
| ES (1) | ES2643465T3 (es) |
| HK (1) | HK1169961A1 (es) |
| MX (1) | MX2012006077A (es) |
| MY (1) | MY162324A (es) |
| NZ (1) | NZ599792A (es) |
| PE (1) | PE20121636A1 (es) |
| SG (1) | SG181089A1 (es) |
| TN (1) | TN2012000182A1 (es) |
| WO (1) | WO2011063770A2 (es) |
| ZA (1) | ZA201203762B (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2655409A4 (en) | 2010-12-22 | 2015-07-01 | Univ Leland Stanford Junior | SUPERAGONISTS AND ANTAGONISTS OF INTERLEUKIN-2 |
| EP3049445A4 (en) | 2013-09-24 | 2017-10-25 | Medicenna Therapeutics, Inc. | Interleukin-2 fusion proteins and uses thereof |
| AU2015233542B2 (en) | 2014-03-17 | 2020-01-16 | Bundesrepublik Deutschland Letztvertreten Durch Das Robert Koch-Institut Vertreten Durch Seinen Prasidenten | A medicament for use in a method of inducing or extending a cellular cytotoxic immune response |
| US10150802B2 (en) * | 2014-04-24 | 2018-12-11 | The Board Of Trustees Of The Leland Stanford Junior University | Superagonists, partial agonists and antagonists of interleukin-2 |
| US20170157215A1 (en) | 2015-12-04 | 2017-06-08 | Jomoco, Corp. | Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates |
| CN110087681A (zh) | 2016-09-28 | 2019-08-02 | 佐马美国有限公司 | 结合白细胞介素-2的抗体和其用途 |
| CU24483B1 (es) * | 2016-11-15 | 2020-04-02 | Ct Inmunologia Molecular | Método para incrementar los niveles de secreción de la interleucina-2 |
| WO2018170288A1 (en) | 2017-03-15 | 2018-09-20 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
| CN111010866A (zh) | 2017-05-24 | 2020-04-14 | 潘迪恩治疗公司 | 靶向免疫耐受性 |
| CN111201035A (zh) | 2017-06-19 | 2020-05-26 | 梅迪塞纳医疗股份有限公司 | Il-2超激动剂、激动剂及其融合体的用途和方法 |
| AU2018372167B2 (en) | 2017-11-21 | 2023-12-07 | The Board Of Trustees Of The Leland Stanford Junior University | Partial agonists of interleukin-2 |
| US10174092B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| MX2020009857A (es) * | 2018-03-28 | 2021-01-08 | Ascendis Pharma Oncology Div A/S | Conjugados de interleucina-2 (il-2). |
| CA3094112A1 (en) | 2018-03-28 | 2019-10-03 | Bristol-Myers Squibb Company | Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use |
| WO2019237079A2 (en) * | 2018-06-07 | 2019-12-12 | Xiaolong Zhang | Pharmaceutical composition containing fusion protein and use thereof |
| US20220403001A1 (en) | 2018-06-12 | 2022-12-22 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| JP2022533702A (ja) | 2019-05-20 | 2022-07-25 | パンディオン・オペレーションズ・インコーポレイテッド | ＭＡｄＣＡＭ標的化免疫寛容 |
| JP7303391B2 (ja) | 2020-01-14 | 2023-07-04 | シンセカイン インコーポレイテッド | バイアス型ｉｌ２ムテイン、方法、および組成物 |
| WO2021168079A1 (en) | 2020-02-21 | 2021-08-26 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a cd39 effector |
| MX2023002648A (es) * | 2020-09-04 | 2023-04-05 | Shandong Simcere Biopharmaceutical Co Ltd | Mutante de il-2 y aplicacion de este. |
| EP4232071A4 (en) | 2020-10-23 | 2024-08-28 | Asher Biotherapeutics Inc | FUSIONS WITH CD8 ANTIGEN-BINDING MOLECULES TO MODULATE IMMUNE CELL FUNCTION |
| EP4236962A1 (en) | 2020-10-29 | 2023-09-06 | Bristol-Myers Squibb Company | Fusion proteins for the treatment of disease |
| US20240287454A1 (en) | 2021-04-30 | 2024-08-29 | Tigen Pharma Sa | Single vessel expansion of lymphocytes |
| WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| WO2023193015A1 (en) | 2022-04-01 | 2023-10-05 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
| WO2024097864A1 (en) | 2022-11-02 | 2024-05-10 | Tigen Pharma Sa | Expansion of lymphocytes |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4853332A (en) | 1982-10-19 | 1989-08-01 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins |
| US4959314A (en) | 1984-11-09 | 1990-09-25 | Cetus Corporation | Cysteine-depleted muteins of biologically active proteins |
| US5116943A (en) | 1985-01-18 | 1992-05-26 | Cetus Corporation | Oxidation-resistant muteins of Il-2 and other protein |
| JP3024311B2 (ja) | 1991-10-03 | 2000-03-21 | 味の素株式会社 | Ｉｌ−２受容体重鎖に結合するポリペプチド |
| US5229109A (en) | 1992-04-14 | 1993-07-20 | Board Of Regents, The University Of Texas System | Low toxicity interleukin-2 analogues for use in immunotherapy |
| US5635597A (en) | 1994-05-27 | 1997-06-03 | Affymax Technologies, N.V. | Peptides that bind IL-2 receptors |
| US6955807B1 (en) * | 1998-05-15 | 2005-10-18 | Bayer Pharmaceuticals Corporation | IL-2 selective agonists and antagonists |
| US6168785B1 (en) | 1998-07-16 | 2001-01-02 | Institut Pasteur | Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents |
| WO2000011028A2 (en) | 1998-08-21 | 2000-03-02 | Yeda Research And Development Co. Ltd. | Anti-inflammatory peptides derived from il-2 and analogues thereof |
| WO2003048334A2 (en) | 2001-12-04 | 2003-06-12 | Merck Patent Gmbh | Immunocytokines with modulated selectivity |
| WO2005007121A2 (en) | 2003-07-18 | 2005-01-27 | Massachusetts Institute Of Technology | Mutant interleukin-2(il-2) polypeptides |
| WO2008003473A2 (en) * | 2006-07-06 | 2008-01-10 | Merck Patent Gmbh | Compositions and methods for enhancing the efficacy of il-2 mediated immune responses |
| US8906356B2 (en) | 2007-11-05 | 2014-12-09 | Massachusetts Institute Of Technology | Mutant interleukin-2 (IL-2) polypeptides |
| DE102008023820A1 (de) * | 2008-05-08 | 2009-11-12 | Aicuris Gmbh & Co. Kg | Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen |
-
2009
- 2009-11-27 CU CU20090203A patent/CU23734A1/es active IP Right Grant
-
2010
- 2010-11-25 AR ARP100104366A patent/AR079197A1/es active IP Right Grant
- 2010-11-26 WO PCT/CU2010/000005 patent/WO2011063770A2/es active Application Filing
- 2010-11-26 BR BR112012012025A patent/BR112012012025B8/pt not_active IP Right Cessation
- 2010-11-26 EA EA201290395A patent/EA021867B1/ru not_active IP Right Cessation
- 2010-11-26 JP JP2012540281A patent/JP5680661B2/ja active Active
- 2010-11-26 US US13/512,429 patent/US8759486B2/en active Active
- 2010-11-26 MX MX2012006077A patent/MX2012006077A/es active IP Right Grant
- 2010-11-26 NZ NZ599792A patent/NZ599792A/en unknown
- 2010-11-26 MY MYPI2012002130A patent/MY162324A/en unknown
- 2010-11-26 EP EP10803437.2A patent/EP2505206B1/en active Active
- 2010-11-26 AU AU2010324254A patent/AU2010324254B2/en active Active
- 2010-11-26 CA CA2781173A patent/CA2781173C/en active Active
- 2010-11-26 SG SG2012039053A patent/SG181089A1/en unknown
- 2010-11-26 ES ES10803437.2T patent/ES2643465T3/es active Active
- 2010-11-26 PE PE2012000720A patent/PE20121636A1/es not_active Application Discontinuation
- 2010-11-26 CN CN201080053369.9A patent/CN102665754B/zh active Active
- 2010-11-26 KR KR1020127010828A patent/KR101484590B1/ko active IP Right Grant
-
2012
- 2012-04-17 EC ECSP12011803 patent/ECSP12011803A/es unknown
- 2012-04-20 TN TNP2012000182A patent/TN2012000182A1/en unknown
- 2012-04-23 CL CL2012001030A patent/CL2012001030A1/es unknown
- 2012-05-23 ZA ZA2012/03762A patent/ZA201203762B/en unknown
- 2012-06-06 CO CO12095471A patent/CO6501124A2/es not_active Application Discontinuation
- 2012-10-30 HK HK12110868.4A patent/HK1169961A1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR079197A1 (es) | Polipeptidos inmunomoduladores derivados de la il-2 y su uso terapeutico en cancer y en infecciones cronicas | |
| BR112017001940A2 (pt) | proteínas de fusão de interleucina-2/receptor alfa de interleucina-2 e processos de uso | |
| CL2013003634A1 (es) | Complejo que comprende una proteina de fusion que comprende, un peptido viral, peptido conector, microglobulina beta 2 , peptido conector, dominios extracelulares alfa 1, 2 y 3 de mhc de clase i y un tercer peptido conector; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso | |
| CU23923B1 (es) | Polipéptidos derivados de la il-2 con actividad agonista | |
| CL2018000232A1 (es) | Mezcla de péptidos (divisional solicitud 201601405) | |
| BR112016012538A2 (pt) | peptídeos citotóxicos e conjugados dos mesmos | |
| EA201591766A1 (ru) | Мутеины интерлейкина-2 для экспансии регуляторных т-клеток | |
| CO7010783A2 (es) | Proteína naglu humana recombinante y usos de la misma | |
| BR112016029848A2 (pt) | proteínas de fusão mic-1 e utilizações das mesmas | |
| MX353165B (es) | Vacunas contra el cancer cerebral basadas en peptido alfa 2 del receptor de interleucina 13. | |
| BR112016002753A2 (pt) | anticorpos contra o inibidor-1 de ativador de plasminogênio (pai-1) e usos dos mesmos | |
| WO2015183995A3 (en) | Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof | |
| UY38069A (es) | Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico | |
| AR114324A1 (es) | Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico | |
| AR114323A1 (es) | Péptidos de la cadena b de la relaxina modificados y su uso terapéutico | |
| PH12016500708A1 (en) | Recombinant glycoproteins and uses thereof | |
| BR112015022730A2 (pt) | formulações de rfviii, método para conjugação covalente de rfviii com um polímero biocompatível e uso de rfviii no preparo de formulação de rfviii para tratamento de hemofilia a | |
| CO7400865A2 (es) | Polipeptidos derivados del tgfbeta y sus usos | |
| AR098154A1 (es) | Glicoproteínas recombinantes y sus usos | |
| EA201992746A2 (ru) | Рекомбинантные гликопротеиды и их применения | |
| RU2015110658A (ru) | Вакцина на основе рекомбинантных белков для терапии ротавирусной инфекции |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |